Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286442 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus
A Phase 3 study of Diabetes Mellitus, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 527
- Enrollment target
- 20
- Study locations
NCT00286442: Completed Phase 3 study of Diabetes Mellitus, sponsored by Takeda.
NCT00286442 is a Phase 3 study of Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 527 participants, below the 1,865-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00286442, a Phase 3 study of Diabetes Mellitus, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 527 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.
Primary Outcome
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Alogliptin and metformin
Study Locations (20)
California
- - Anaheim
- - Artesia
- - Fresno
- - Los Angeles
- - Mission Viejo
- - Northridge
- - Orange
- - San Diego
- - Walnut Creek
Florida
- - Cocoa Beach
- - Longwood
- - Ocala
- - Ocoee
- - Saint Cloud
Indiana
- - Avon
- - Elkhart
Arizona
- - Phoenix
Colorado
- - Denver
District of Columbia
- - Washington D.C.
Hawaii
- - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
What the finished NCT00286442 record still lists
NCT00286442 is an interventional study that assigns participants to a tested intervention. The registered 527 participants enrollment target is mid-sized for trials with a published cap, below the 1,865-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.
NCT00286442 names 20 study sites across 7 states, led by California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT00286442 about?
NCT00286442 is a clinical study titled "Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.
What is the current status of trial NCT00286442?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 527 participants. The study started on 2006-03. Estimated completion is 2007-06.
What conditions does trial NCT00286442 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT00286442?
The interventions under investigation include: Metformin (DRUG), Alogliptin and metformin (DRUG).
Who is sponsoring clinical trial NCT00286442?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00286442 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00286442's enrollment target sits among peer trials
527 46th of 208 higher than 163 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
COMPLETED · Phase 3
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373017 · 528 participants · NA
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
- NCT05634252 · 528 participants · Phase 3
Undergraduate Skin Cancer Prevention Trial
- NCT06383273 · 528 participants · Phase 3
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
- NCT06470243 · 528 participants · Phase 3
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia